Tech Company Financing Transactions
Oblenio Bio Funding Round
Oblenio Bio closed a $62 million Series B financing round on 6/25/2026. Backers included Pfizer Venture Investments, Aditum Bio and Deep Track Capital.
Transaction Overview
Company Name
Announced On
6/25/2026
Transaction Type
Venture Equity
Amount
$62,000,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds for the initial clinical development of LBL-051, its tri-specific T-cell engager, designed to achieve a broad immune system reset to treat patients suffering from a range of refractory autoimmune diseases.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
4 Maguire Road
Lexington, MA 02421
USA
Lexington, MA 02421
USA
Phone
Undisclosed
Website
Email Address
Overview
Oblenio Bio aims to transform the treatment of refractory autoimmune diseases, putting the promise of immune reset in reach for millions of patients. Oblenio Bio is pursuing broad immune reset as a transformative therapy for refractory autoimmune diseases through our LBL-051 T-cell engager.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Samantha Truex
Chief Medical Officer
Tapan Maniar
Chief Operating Officer
Laurie Berggren
Vice President
Sara Burke
VP - Bus. Development
Rohan Lathia
VP - Engineering
Tara Barreira
VP - Operations
Christine Cornwell
Browse more venture capital transactions:
Prev: 6/25/2026: Revora venture capital transaction
Next: 6/25/2026: SAZO venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on tech company VC transactions. All VC database entries reported here come from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs